From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Podcasts|February 19, 2021
Pharmacy Focus Episode 18: Performance Measures and Leadership in Pharmacy
The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Advertisement
In this week’s episode, we will be discussing performance measures in pharmacies and leadership techniques for every pharmacist with Jesse McCullough, who has a background in retail and performance measurement. If you would like to nominate a pharmacist or pharmacy staff member as a Pharmacy Hero, email AAntrim@pharmacytimes.com!
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5